ES2166752T3 - Asociacion entre un retrovirus relacionado con el virus de inmunodeficiencia humana y el sindrome de sjogren. - Google Patents

Asociacion entre un retrovirus relacionado con el virus de inmunodeficiencia humana y el sindrome de sjogren.

Info

Publication number
ES2166752T3
ES2166752T3 ES91910537T ES91910537T ES2166752T3 ES 2166752 T3 ES2166752 T3 ES 2166752T3 ES 91910537 T ES91910537 T ES 91910537T ES 91910537 T ES91910537 T ES 91910537T ES 2166752 T3 ES2166752 T3 ES 2166752T3
Authority
ES
Spain
Prior art keywords
sjogren
syndrome
retrovirus
human immunodeficiency
new
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES91910537T
Other languages
English (en)
Inventor
Robert F Garry Jr
Cesar D Fermin
Steve S Alexander Jr
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Tulane University
Original Assignee
Tulane University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tulane University filed Critical Tulane University
Application granted granted Critical
Publication of ES2166752T3 publication Critical patent/ES2166752T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56983—Viruses
    • G01N33/56988—HIV or HTLV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/10022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
    • C12N2740/15021—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
    • C12N2740/15022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
    • C12N2740/15051—Methods of production or purification of viral material
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/10—Musculoskeletal or connective tissue disorders
    • G01N2800/101—Diffuse connective tissue disease, e.g. Sjögren, Wegener's granulomatosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/10—Musculoskeletal or connective tissue disorders
    • G01N2800/101—Diffuse connective tissue disease, e.g. Sjögren, Wegener's granulomatosis
    • G01N2800/102—Arthritis; Rheumatoid arthritis, i.e. inflammation of peripheral joints
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/24—Immunology or allergic disorders
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S930/00—Peptide or protein sequence
    • Y10S930/01—Peptide or protein sequence
    • Y10S930/22—Viral peptide or viral protein
    • Y10S930/221—Retrovirus related, or human immunodeficiency virus related, or simian immunodeficiency virus related

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • General Physics & Mathematics (AREA)
  • Wood Science & Technology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Pathology (AREA)
  • AIDS & HIV (AREA)
  • Rheumatology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)

Abstract

LA INVENCION SE REFIERE A LA PREPARACION PURIFICADA DE UN NUEVO RETROVIRUS, A METODOS DE DIAGNOSIS Y EL TRATAMIENTO DEL SINDROME DE "SJOGREN", A NUEVAS LINEAS CELULARES, Y A SISTEMAS DE MODELO PARA EL ESTUDIO DE ENFERMEDADES ANTIINMNUNES Y DEL SIDA. LA INVENCION SE BASA, EN PARTE, EN EL DESCUBRIMIENTO DE UN NUEVO RETROVIRUS QUE ES ANTIGENICAMENTE SIMILAR AL VIRUS DE LA INMUNODEFICIENCIA HUMANA PERO QUE PARECE COMPRENDER UNA TRANSCRIPTASA INVERSA FUNCIONALMENTE DISTINTA. DE ACUERDO CON LA INVENCION, EL SINDROME DE "SJOGREN" ASI COMO OTRAS ENFERMEDADES ANTIINMUNES PUEDEN DIAGNOSTICARSE, Y SU EVOLUCION CLINICA PUEDE SER MONITORIZADA, DEMOSTRANDO LA PRESENCIA DE ANTICUERPOS ANTIRETROVIRALES Y / O MIDIENDO LOS NIVELES DE TALES ANTICUERPOS. ALTERNATIVAMENTE, EL SINDROME DE "SJOGREN" U OTRAS ENFERMEDADES ANTIINMUNES PUEDEN DIAGNOSTICARSE O MONITORIZARSE MIDIENDO DIRECTA O INDIRECTAMENTE LA PRESENCIA DE PARTICULAS VIRALES EN LAS CELULAS DE UN PACIENTE. ADEMAS, DE ACUERDO CON LA INVENCION, LOS PACIENTES QUE SUFRAN EL SINDROME DE "SJOGREN" Y QUE HAN DEMOSTRADO QUE PRESENTAN EL RETROVIRUS O ANTICUERPOS ANTIRETROVIRALES PUEDEN SER TRATADOS CON AGENTES QUE SE CONOCEN UTILES EN EL TRATAMIENTO DE ENFERMEDADES RETROVIRALES, INCLUYENDO PERO NO ESTANDO LIMITADAS A AGENTES QUE INTERFIERAN CON LA FUNCION DE LA TRANSCRIPTASA INVERSA, TAL COMO, POR EJEMPLO, ANALOGOS NUCLEOSIDOS (POR EJ. ZODIVUDINA O DIDEOXINOSINA).
ES91910537T 1990-05-21 1991-05-20 Asociacion entre un retrovirus relacionado con el virus de inmunodeficiencia humana y el sindrome de sjogren. Expired - Lifetime ES2166752T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US52634990A 1990-05-21 1990-05-21

Publications (1)

Publication Number Publication Date
ES2166752T3 true ES2166752T3 (es) 2002-05-01

Family

ID=24096977

Family Applications (1)

Application Number Title Priority Date Filing Date
ES91910537T Expired - Lifetime ES2166752T3 (es) 1990-05-21 1991-05-20 Asociacion entre un retrovirus relacionado con el virus de inmunodeficiencia humana y el sindrome de sjogren.

Country Status (10)

Country Link
US (1) US5344774A (es)
EP (3) EP1152243A1 (es)
JP (1) JP3128238B2 (es)
AT (1) ATE211168T1 (es)
AU (1) AU663290B2 (es)
CA (1) CA2083493C (es)
DE (1) DE69132875T2 (es)
DK (1) DK0535021T3 (es)
ES (1) ES2166752T3 (es)
WO (1) WO1991018089A1 (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK0713397T3 (da) * 1992-03-24 2003-03-31 United Cancer Res Inst Vaccine indeholdende levende virus
US5602023A (en) * 1992-03-24 1997-02-11 Csatary; Laszlo K. Pharmaceutical product containing live, stabilized virus for the therapy of viral and malignant diseases and process for preparing the same
FR2705234B1 (fr) * 1993-05-19 1995-08-04 Geffard Michel Utilisation de molécules reconnues par des autoanticorps de sérums humains pour le diagnostic ou le traitement du SIDA.
US5580772A (en) * 1994-05-17 1996-12-03 The Administrattors Of The Tulane Educational Fund Association between a novel human intracisternal A-type retroviral particle-type II (HIAP-II) and idiopathic CD4+ T-lymphocytopenia (ICL)
CA2191099A1 (en) * 1994-05-23 1995-11-30 Howard B. Urnovitz Non-hiv antibodies as disease markers
GB9509245D0 (en) * 1995-05-05 1995-06-28 Griffiths David J Novel retrovirus and diagnostic methods
US7122207B2 (en) * 1998-05-22 2006-10-17 Bristol-Myers Squibb Company High drug load acid labile pharmaceutical composition
AU2002303816B2 (en) * 2001-05-21 2008-02-14 The Research Foundation Of The State University Of New York TSG101 as inhibitors of HIV production

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1989011285A1 (en) * 1988-05-23 1989-11-30 Steffen Gay Diagnostics and therapy for rheumatoid arthritis

Also Published As

Publication number Publication date
AU663290B2 (en) 1995-10-05
CA2083493C (en) 2006-09-19
US5344774A (en) 1994-09-06
JPH05506359A (ja) 1993-09-22
ATE211168T1 (de) 2002-01-15
EP0535021A4 (en) 1993-09-29
DE69132875D1 (de) 2002-01-31
EP1314429A3 (en) 2003-06-04
AU7959291A (en) 1991-12-10
EP1314429A2 (en) 2003-05-28
DE69132875T2 (de) 2002-08-22
JP3128238B2 (ja) 2001-01-29
CA2083493A1 (en) 1991-11-22
DK0535021T3 (da) 2002-04-15
WO1991018089A1 (en) 1991-11-28
EP0535021B1 (en) 2001-12-19
EP1152243A1 (en) 2001-11-07
EP0535021A1 (en) 1993-04-07

Similar Documents

Publication Publication Date Title
Jackson et al. Passive immunoneutralisation of human immunodeficiency virus in patients with advanced AIDS
Ito et al. Inhibitory effect of dextran sulfate and heparin on the replication of human immunodeficiency virus (HIV) in vitro
Gellis The year Book of pediatrics
TNSN91029A1 (fr) Les analogues du nucleoside de 1,3-oxathiolane
NO821832L (no) Fremgangsmaate for fremstilling av allergenholdige kapsler
ATE183640T1 (de) Kombinierte virustatikum-antimediator-behandlung (covam) von gewöhnlichen erkältungen
ATE50260T1 (de) Purinderivate, verfahren zu ihrer herstellung und pharmazeutische zubereitung.
ATE87484T1 (de) Physiologisch aktive substanzen, verfahren zu ihrer herstellung und diese enthaltende pharmazeutische zusammensetzungen.
ES2146199T3 (es) Utilizacion de la arginina como inmunoestimulante.
ES2166752T3 (es) Asociacion entre un retrovirus relacionado con el virus de inmunodeficiencia humana y el sindrome de sjogren.
Mitchell et al. Mismatched double-stranded RNA (ampligen) reduces concentration of zidovudine (azidothymidine) required for in-vitro inhibition of human immunodeficiency virus
CH306781A (fr) Tampon destiné à servir de support à des médicaments dans le traitement de cavités du corps humain, notamment dans le traitement des maladies de l'anus.
ES2061495T3 (es) Peptidos relacionados con el virus htlv-iii, anticuerpos para los peptidos, vacunas, inmunizacion activa y pasiva contra el virus del sida y prueba diagnostica para la deteccion serologica del virus del sida.
Yu et al. Killing of primary CD4+ T cells by non-syncytium-inducing macrophage-tropic human immunodeficiency virus type 1.
SE8701628D0 (sv) Medel for analys mm
AR247404A1 (es) Composicion peptidica de uso exclusivo para el diagnostico de la enfermedad de la malaria y procedimiento de sintesis de dicha composicion peptidica
MELDER et al. Cytotoxic activity against HIV-infected monocytes by recombinant interleukin 2-activated natural killer cells
Stoneburner et al. Tuberculosis and acquired immunodeficiency syndrome-- New York City.
HUP9901161A2 (hu) Módosított aktivitású hibrid VIII. faktor
Favour Leucocyte blockade of in vitro tuberculin cytolysis.
DE3583400D1 (de) Zubereitungen und verfahren zum schutz von t-lymphozyten gegen das krankheitsagens von lymphadenopathie und vom erworbenen immundepressionsyndrom.
HECHT et al. Treatment of epidemic keratoconjunctivitis with idoxuridine (IUDR)
Luce The Acquired Immunodeficiency Syndrome: A report on the second international conference on AIDS
Gilles et al. Lassa fever: retrospective diagnosis of two patients seen in Great Britain in 1971.
Rutherford The epidemiology of human immunodeficiency virus and the acquired immunodeficiency syndrome